Dual orexin receptor antagonist (DORA)

Quviviq (daridorexant) Withdrawal

Daridorexant, the newest of the orexin-antagonist sleep medications, was designed with the dependence problems of older hypnotics in mind. In clinical trials it showed no meaningful withdrawal syndrome and minimal rebound insomnia after stopping, in contrast to benzodiazepines and Z-drugs (Ambien, Lunesta). The main thing people notice on stopping is the return of the original insomnia rather than a true withdrawal state.

By Dr. Ben Soffer, DO — board-certified physician, at-home ketamine therapy in Florida and New Jersey.

Half-life

Approximately 8 hours - engineered to cover the night and clear by morning, which also helps limit next-day grogginess.

Withdrawal timeline

OnsetFirst 1-3 nights after stopping

Any change is usually just the reappearance of the underlying insomnia; a mild, short-lived uptick in sleeplessness (rebound) is possible but typically modest.

PeakWithin the first week

If rebound insomnia occurs, it is generally at its most noticeable in the first several nights and then eases.

ResolutionDays to about a week

Sleep usually returns to its pre-treatment baseline within days. Persistent insomnia beyond that reflects the underlying sleep problem, not the medication.

Common symptoms

  • Return of the original insomnia
  • Mild, short-lived rebound sleeplessness

Less common

  • Vivid dreams as sleep architecture readjusts
  • Daytime tiredness while sleep re-stabilizes

Tapering guidance

  • A strict taper is usually not required given the low dependence potential, but a brief step-down after long-term nightly use can smooth any rebound.
  • If insomnia is tied to a mood or anxiety disorder, address that alongside stopping the medication.
  • Coordinate with the prescribing physician, especially if the insomnia is part of a broader psychiatric picture.

Where ketamine therapy fits

Ketamine therapy does not treat daridorexant discontinuation. As with the other orexin antagonists, it is relevant when insomnia is a downstream symptom of depression or anxiety: treating the underlying mood disorder often improves sleep. Coordinate with the prescribing physician to target the root cause.

Frequently asked questions

Does Quviviq cause withdrawal?

Clinical trials showed no significant withdrawal syndrome and only minimal rebound insomnia after stopping daridorexant. Like Belsomra and Dayvigo, it has low dependence potential, unlike benzodiazepines or Z-drugs such as Ambien and Lunesta.

Will my insomnia come back if I stop Quviviq?

The most common experience on stopping is the return of the original insomnia rather than a new withdrawal effect. A mild, short-lived rebound in the first few nights is possible but usually modest, and sleep typically settles to baseline within days.

Do I need to taper Quviviq?

A strict taper is usually not necessary given the low dependence potential, though a brief step-down after long-term nightly use can ease any rebound. Coordinate with your prescriber, especially if the insomnia is part of a mood or anxiety disorder.

Can ketamine therapy address the insomnia underneath?

When insomnia stems from depression or anxiety, treating the mood disorder often improves sleep. Ketamine is one option for those conditions; coordinate with your prescriber to identify and target the underlying driver.

Important: This page is informational and does not constitute medical advice or a recommendation to start, stop, or change any medication. Tapering psychiatric medications should always be coordinated with the prescribing physician. Compounded ketamine for anxiety, depression, PTSD, and chronic pain is not FDA approved.

Browse all medication withdrawal guides.